Bridgebio Pharma Inc (BBIO) financials
Bridgebio Pharma revenue and earnings by year
Bridgebio Pharma's revenue was $502 million in the fiscal year to December 31, 2025, up 126.3% from the year before. Net income was -$725 million, -144.4% of revenue. Since the fiscal year to December 31, 2019, revenue has grown 52.1% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 7 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 502 | 222 | 9 | 78 | 70 | 8 | 41 |
| Revenue growth | 126.3% | 2285.3% | -88.0% | 11.4% | 745.1% | -79.7% | — |
| Gross profit | 481 | 218 | 7 | 74 | 67 | — | 38 |
| Gross margin | 95.8% | 98.3% | 73.7% | 95.6% | 95.5% | — | 93.8% |
| Operating income | -523 | -593 | -607 | -512 | -577 | -474 | -266 |
| Operating margin | -104.2% | -267.2% | -6528.8% | -659.6% | -827.1% | -5752.0% | -656.4% |
| Net income | -725 | -536 | -643 | -481 | -563 | -449 | -261 |
| Net margin | -144.4% | -241.4% | -6913.9% | -619.7% | -806.9% | -5439.7% | -642.5% |
| Diluted EPS | -$3.78 | -$2.88 | -$3.95 | -$3.26 | -$3.92 | -$3.80 | -$2.50 |
| Free cash flow | -447 | -522 | -529 | -525 | -511 | -407 | -256 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open BBIO in Markets.
See also: BBIO returns
No forecast, no recommendation. This page describes Bridgebio Pharma Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.